Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how - 2Woman charged in unprovoked stabbing of tourist changing baby's diaper in Macy’s Herald Square store
- 3RFK Jr. says fewer flu shots for kids may be 'better.' What experts say.
- 4Figure out How to Reveal Stowed away Open Record Rewards
- 5Scientists find new clues to why female fertility declines with age
- When does Spotify Wrapped come out? The music streamer says 'soon.'
- Manual for Financial plan Agreeable PC
- Party Urban areas of the World
- I'm an 83-year-old yoga instructor. I'm not your typical grandma — I still work to feel fulfilled and supplement my Social Security.
- Scientists document a death from a meat allergy tied to certain ticks
- First Phosphate advances battery-grade phosphate project as analysts highlight strategic Federal support
- Interoceanic Train derails in southern Mexico, injuring at least 15 and halting traffic on line
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- 5 Pizza Fixings That Characterize Your Character
